REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On February6, 2019, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December31, 2018. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release, dated February6, 2019, Reporting Fourth Quarter and Full Year 2018 Financial and Operating Results.
REGENERON PHARMACEUTICALS INC Exhibit
EX-99.1 2 exhibit991q42018.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results•Fourth quarter 2018 revenues were $1.93 billion,…
To view the full exhibit click here
About REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.
